RxDoctor Payments Data

Scott Bassett, MD

Interventional Cardiology · The Woodlands, TXNPI 1073847042

Payments from drug & device makers

$37,914in general payments, 2019–2025

Across 335 payments — averaging $113.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$24K
  • Boston Scientific$4K
  • Medtronic$3K
  • Abbott$3K
  • Biotronik Inc.$909
  • Abiomed$511
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$20,00053%
  • Travel & lodging$5,19614%
  • Food & beverage$12,62033%
  • Education$980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,914 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$276,304
Medicare patients
954
Services billed
3,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban345$391,908
XareltoRivaroxaban147$150,634
EntrestoSacubitril/Valsartan125$144,875
JardianceEmpagliflozin103$112,153
MultaqDronedarone Hcl32$51,115
BrilintaTicagrelor57$38,234
Praluent PenAlirocumab34$24,510
Repatha SureclickEvolocumab24$19,344
FarxigaDapagliflozin Propanediol15$15,995
NexletolBempedoic Acid20$9,990
VascepaIcosapent Ethyl14$8,301
Midodrine Hcl30$6,210
Nebivolol Hcl64$5,196
Metoprolol Succinate316$4,933
Flecainide Acetate103$4,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$259$391,908345 claims
Johnson & JohnsonXarelto$97$150,634147 claims
NovartisEntresto$137$144,875125 claims
Boehringer IngelheimJardiance$198$112,153103 claims
AstraZenecaBrilinta, Farxiga$108$54,22872 claims
Sanofi-aventis U.S. LLCMultaq$33$51,11532 claims
Esperion Therapeutics, Inc.Nexletol$65$9,99020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →